July 17, 2023 Khan M. Siddiqui Re: Schedule and Salary ModificationHyperfine, Inc. • July 18th, 2023 • Electromedical & electrotherapeutic apparatus
Thank you for your recent discussions regarding the proposed modification to your schedule and compensation. On behalf of Hyperfine, Inc. (the “Company”), I’ve outlined below our understanding of the agreement regarding this modification to your role as Chief Medical Officer and Chief Strategy Officer. Please review, and if you agree, sign where indicated below. Of course, please do not hesitate to contact me with any questions.
